Malignant Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Malignant Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major malignant mesothelioma markets reached a value of US$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12.2 Billion by 2034, exhibiting a growth rate (CAGR) of 6.5% during 2024-2034.

The malignant mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Malignant Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant mesothelioma refers to a rare and aggressive form of cancer characterized by the uncontrolled growth of abnormal cells in the mesothelium, a protective tissue that lines many of the body's internal organs. As the cancerous cells multiply and accumulate, they can form tumors, impair organ function, and spread to various other parts of the body (metastasize). The symptoms of the illness can vary depending on the affected area, but common signs include chest pain, shortness of breath, cough, fatigue, abdominal swelling and pain, weight loss, bowel obstruction, weakness, etc. The diagnosis of malignant mesothelioma is typically made by reviewing a patient's clinical features, medical history, and physical examination. Numerous imaging studies, like computed tomography (CT) scans, chest X-rays, positron emission tomography (PET) scans, etc., are recommended to visualize the presence of abnormal growths and their location. The healthcare provider may also conduct blood tests to evaluate certain biomarkers, such as soluble mesothelin-related peptides and fibulin-3, that may be indicative of the condition. Furthermore, a tissue biopsy is performed to confirm the presence of mesothelioma and determine its type.

The increasing cases of exposure to asbestos fibers, which release reactive oxygen species and inflammatory molecules that can damage DNA within the cells, are primarily driving the malignant mesothelioma market. In addition to this, the rising incidence of variations in tumor suppressor genes that are responsible for inhibiting cell division and promoting apoptosis is creating a positive outlook for the market. Moreover, the widespread adoption of photodynamic therapy, since it involves using a photosensitizing agent and light to selectively destroy tumors, thereby alleviating symptoms and improving the quality of life for patients, is further bolstering the market growth. Apart from this, the inflating application of immune checkpoint inhibitors, such as pembrolizumab, nivolumab, ipilimumab, etc., to promote a favorable safety profile with fewer adverse effects is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which offer a way to overcome drug resistance by targeting specific genetic mutations or signaling pathways involved in resistance mechanisms, is expected to drive the malignant mesothelioma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the malignant mesothelioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for malignant mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant mesothelioma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the malignant mesothelioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the malignant mesothelioma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current malignant mesothelioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the malignant mesothelioma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the malignant mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the malignant mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of malignant mesothelioma across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant mesothelioma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant mesothelioma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with malignant mesothelioma across the seven major markets?
What is the size of the malignant mesothelioma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of malignant mesothelioma?
What will be the growth rate of patients across the seven major markets?

Malignant Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for malignant mesothelioma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant mesothelioma market?
What are the key regulatory events related to the malignant mesothelioma market?
What is the structure of clinical trial landscape by status related to the malignant mesothelioma market?
What is the structure of clinical trial landscape by phase related to the malignant mesothelioma market?
What is the structure of clinical trial landscape by route of administration related to the malignant mesothelioma market?